Cure8 news brief
If PALI-2108 proves safe and effective in Phase 2 trials, it could add a new oral treatment option for people with ulcerative colitis and Crohn’s disease. Early Phase 1 signals and a funded Phase 2 program mean the drug’s development is actively progressing, which patients and clinicians may want to follow.
Patients with ulcerative colitis or Crohn’s disease interested in emerging oral therapies; clinicians and researchers tracking new IBD drugs and PDE4-targeted approaches; investors following biotech clinical development.
Palisade Bio says it will begin a Phase 2 ASCENTRA-UC trial for PALI-2108 in the second half of 2026 and aims to file an IND for a Phase 2 Crohn’s trial in the same timeframe.
The company reported favorable Phase 1 safety and some clinical responses in UC and fibrostenotic Crohn’s patients, per the release, and expects primary efficacy results from ASCENTRA-UC in late 2027. The announcement is a corporate/financial update: it also summarizes quarterly financials (cash on hand and R&D expense) and investor-focused metrics.
The clinical timelines, early Phase 1 observations, and planned presentations at conferences are described in the release but should be seen as company-reported plans rather than independent clinical reporting.
This article reproduces a company press release summarized by QuiverQuant. Planned trial start dates and result timelines are company estimates and do not represent completed evidence of efficacy. Phase 1 observations described as “promising” are preliminary; Phase 2 results will be needed to assess benefit and safety more reliably.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If you or a loved one follow emerging IBD treatments, this update signals a new PALI-2108 program moving into Phase 2 for ulcerative colitis and planned Phase 2 testing in Crohn’s disease, plus a company focus on...
This press release reports phase 2 evidence that a new experimental antibody (duvakitug) showed clinical, endoscopic, and histologic improvements in both UC and Crohn’s disease, which could lead to a new treatment option...
The Phase 2b results suggest the investigational TL1A drug duvakitug improved clinical and endoscopic outcomes versus placebo in both ulcerative colitis and Crohn’s disease, which could expand future treatment options if...
